Techniques for loading technetium-99m and rhenium-186/188 radionuclides into pre-formed liposomes for diagnostic imaging and radionuclide therapy
- PMID: 20013416
- DOI: 10.1007/978-1-60761-447-0_32
Techniques for loading technetium-99m and rhenium-186/188 radionuclides into pre-formed liposomes for diagnostic imaging and radionuclide therapy
Abstract
Liposomes can serve as carriers of radionuclides for diagnostic imaging and therapeutic applications. Herein, procedures are outlined for radiolabeling liposomes with the gamma-emitting radionuclide, technetium-99m ((99m)Tc), for non-invasive detection of disease and for monitoring the pharmacokinetics and biodistribution of liposomal drugs, and/or with therapeutic beta-emitting radionuclides, rhenium-186/188 ((186/188)Re), for radionuclide therapy. These efficient and practical liposome radiolabeling methods use a post-labeling mechanism to load (99m)Tc or (186/188)Re into pre-formed liposomes prepared in advance of the labeling procedure. For all liposome radiolabeling methods described, a lipophilic chelator is used to transport (99m)Tc or (186/188)Re across the lipid bilayer of the pre-formed liposomes. Once within the liposome interior, the pre-encapsulated glutathione or ammonium sulfate (pH) gradient provides for stable entrapment of the (99m)Tc and (186/188)Re within the liposomes. In the first method, (99m)Tc is transported across the lipid bilayer by the lipophilic chelator, hexamethylpropyleneamine oxime (HMPAO) and (99m)Tc-HMPAO becomes trapped by interaction with the pre-encapsulated glutathione within the liposomes. In the second method, (99m)Tc or (186/188)Re is transported across the lipid bilayer by the lipophilic chelator, N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), and (99m)Tc-BMEDA or (186/188)Re-BMEDA becomes trapped by interaction with pre-encapsulated glutathione within the liposomes. In the third method, an ammonium sulfate (pH) gradient loading technique is employed using liposomes with an extraliposomal pH of 7.4 and an interior pH of 5.1. BMEDA, which is lipophilic at pH 7.4, serves as a lipophilic chelator for (99m)Tc or (186/188)Re to transport the radionuclides across the lipid bilayer. Once within the more acidic liposome interior, (99m)Tc/(186/188)Re-BMEDA complex becomes protonated and more hydrophilic, which results in stable entrapment of the (99m)Tc/(186/188)Re-BMEDA complex within the liposomes. Since many commercially available liposomal drugs use an ammonium sulfate (pH) gradient for drug loading, these liposomal drugs can be directly radiolabeled with (99m)Tc-BMEDA for non-invasive monitoring of tissue distribution during treatment or with (186/188)Re-BMEDA for combination chemo-radionuclide therapy.
Similar articles
-
Techniques for Loading Technetium-99m and Rhenium-186/188 Radionuclides into Preformed Liposomes for Diagnostic Imaging and Radionuclide Therapy.Methods Mol Biol. 2017;1522:155-178. doi: 10.1007/978-1-4939-6591-5_13. Methods Mol Biol. 2017. PMID: 27837538
-
186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats.J Nucl Med. 2003 Dec;44(12):1992-9. J Nucl Med. 2003. PMID: 14660726
-
Remote-loading labeling of liposomes with (99m)Tc-BMEDA and its stability evaluation: effects of lipid formulation and pH/chemical gradient.J Liposome Res. 2011 Mar;21(1):17-27. doi: 10.3109/08982101003699036. Epub 2010 Mar 24. J Liposome Res. 2011. PMID: 20334497
-
99mTc-Hexamethylpropyleneamine oxime-blue-biotin-liposomes.2008 Mar 11 [updated 2008 Apr 22]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2008 Mar 11 [updated 2008 Apr 22]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641735 Free Books & Documents. Review.
-
Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.Chem Commun (Camb). 2009 Feb 7;(5):493-512. doi: 10.1039/b814903h. Epub 2008 Dec 1. Chem Commun (Camb). 2009. PMID: 19283279 Review.
Cited by
-
Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model.Oncotarget. 2016 Oct 4;7(40):65782-65796. doi: 10.18632/oncotarget.11666. Oncotarget. 2016. PMID: 27588466 Free PMC article.
-
Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes.Mol Pharm. 2012 Sep 4;9(9):2513-22. doi: 10.1021/mp300132f. Epub 2012 Aug 23. Mol Pharm. 2012. PMID: 22894603 Free PMC article.
-
Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.Oncotarget. 2016 May 31;7(22):32866-75. doi: 10.18632/oncotarget.8763. Oncotarget. 2016. PMID: 27096954 Free PMC article.
-
Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging.Bioconjug Chem. 2012 Jun 20;23(6):1322-32. doi: 10.1021/bc300175d. Epub 2012 May 22. Bioconjug Chem. 2012. PMID: 22577859 Free PMC article.
-
Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial.Nat Commun. 2025 Mar 7;16(1):2079. doi: 10.1038/s41467-025-57263-1. Nat Commun. 2025. PMID: 40055350 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous